Gianluca Giannarini

@GGiannarini

Urologist interested in GU cancers | Associate Editor | Office | Views mine

Udine, Italy
Joined December 2013

Tweets

You blocked @GGiannarini

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @GGiannarini

  1. Jan 4

    Poor Outcomes for Patients with Metastatic Castration-resistant with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

    Undo
  2. Jan 3

    Excellent editorial comment by but I am not entirely surprised by low PPV of MRI in AS for 2 reasons: 1. Population enriched with GG1 cancers; 2. Many have post biopsy changes that can negatively affect MRI performance, which makes a case for

    Undo
  3. Jan 1

    I’ll say it again...there are way too many people making way too much money in healthcare, that have nothing to do with actually providing healthcare.

    Undo
  4. Jan 3

    New Scandinavian prospective, multi-centre, randomized trial is comparing radical prostatectomy ± radiation to primary radiation treatment and androgen deprivation in locally advanced . Read the study design and plan here:

    Undo
  5. Jan 2

    Nice review from "larger-volume hospitals had better survival outcomes and fewer complications when compared to smaller hospitals"

    Undo
  6. Jan 2

    Older men on active surveillance for associated w/ ↑ rates of biopsy grade reclassification & prostatectomy grade reclassification

    Undo
  7. Jan 2

    A slide on why prescription drug prices unlike prices of almost all other things like iPhones need to be regulated.

    Show this thread
    Undo
  8. Jan 2

    Ricciardi: «Il governo ha posizioni antiscientifiche, ecco perché mi dimetto»

    Undo
  9. 30 Dec 2018

    In Switzerland, 1998-2009 Exit assisted 71 people to die on the grounds of depression and 24 because they were blind. Our detailed review of all 15 flawed euthanasia and assisted suicide experiments globally.

    Undo
  10. Jan 2

    Cabozantinib for Progressive Metastatic Castration-resistant Following Docetaxel: Combined Analysis of Two Phase 3 Trials

    Undo
  11. 31 Dec 2018

    On this last day of 2018, on behalf of our editorial boards, I would like to thank those who review for our journals. Its a vital role, yet often a

    , , and 7 others
    Undo
  12. 31 Dec 2018

    Mamma, ti eri iscritta a Twitter per seguire i tuoi adorati angeli custodi, quei dottori che nella tua lunga battaglia sono riusciti a darti forza e speranza, rendendo più lievi le tue sofferenze. Ora, , da lassù veglia su di loro e su tutti noi.

    , , and 3 others
    Undo
  13. 29 Dec 2018
    Undo
  14. 30 Dec 2018
    Undo
  15. 29 Dec 2018

    Finally, Ioannidis has a thing or two to say about precision oncology. A thorough and thoughtful review of trial designs.

    Undo
  16. 28 Dec 2018

    Thanks to all who have contributed to and helped make it such a high impact publication already. Keep ‘em coming!

    , , and 7 others
    Undo
  17. 28 Dec 2018

    Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review

    Undo
  18. 27 Dec 2018
    Undo
  19. 26 Dec 2018

    Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

    Undo
  20. 24 Dec 2018

    And, just a week later, a paper in JAMA shows that these low quality seeding trials really do translate into increased prescribing

    Show this thread
    Undo

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·